Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07464145) titled 'A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer' on March 2.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Relmada Therapeutics, Inc.
Condition:
Bladder (Urothelial, Transitional Cell) Cancer
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
Urothelial Carcinoma Bladder
Urothelial Carcinoma Recurrent
Urologic Cancer
Intervention:
Drug: NDV-01 (sustained-release gemcitabine-docetaxel)
Recr...